Robinson, James E.
Hastie, Kathryn M.
Cross, Robert W.
Yenni, Rachael E.
Elliott, Deborah H.
Rouelle, Julie A.
Kannadka, Chandrika B.
Smira, Ashley A.
Garry, Courtney E.
Bradley, Benjamin T. http://orcid.org/0000-0002-8064-9314
Yu, Haini
Shaffer, Jeffrey G.
Boisen, Matt L.
Hartnett, Jessica N.
Zandonatti, Michelle A.
Rowland, Megan M.
Heinrich, Megan L.
MartÃnez-Sobrido, Luis
Cheng, Benson
de la Torre, Juan C.
Andersen, Kristian G.
Goba, Augustine
Momoh, Mambu
Fullah, Mohamed
Gbakie, Michael
Kanneh, Lansana
Koroma, Veronica J.
Fonnie, Richard
Jalloh, Simbirie C.
Kargbo, Brima
Vandi, Mohamed A.
Gbetuwa, Momoh
Ikponmwosa, Odia
Asogun, Danny A.
Okokhere, Peter O.
Follarin, Onikepe A.
Schieffelin, John S.
Pitts, Kelly R.
Geisbert, Joan B.
Kulakoski, Peter C.
Wilson, Russell B.
Happi, Christian T.
Sabeti, Pardis C.
Gevao, Sahr M.
Khan, S. Humarr
Grant, Donald S.
Geisbert, Thomas W.
Saphire, Erica Ollmann
Branco, Luis M.
Garry, Robert F.
Article History
Received: 15 March 2016
Accepted: 7 April 2016
First Online: 10 May 2016
Competing interests
: The Viral Hemorrhagic Fever Consortium (ExternalRef removed) is a public-private partnership of academic and industry scientists who are developing diagnostic tests, therapeutic agents and vaccines for Lassa fever, Ebola and other severe diseases. Tulane University and its various academic and industry partners have filed United States and foreign patent applications on behalf of the VHFC for several technologies that have resulted from these efforts. Technical information may also be kept as trade secrets. If commercial products are developed, consortium members may receive royalties or profits. This does not alter our adherence to all policies of the National Institutes of Health and on sharing data and materials.